Form 4: Arcus Biosciences Chief Accounting Officer Reports Stock Sale

Alexander Azoy, Chief Accounting Officer of Arcus Biosciences, reports selling 1,357 shares of common stock at $14.97 per share on August 13, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 15, 2024, a Form 4 filing was submitted to the SEC by Alexander Azoy, Chief Accounting Officer of Arcus Biosciences.
• The filing reports a sale of 1,357 shares of Arcus Biosciences common stock on August 13, 2024, at a price of $14.97 per share.
• The sale was executed under a Rule 10b5-1 trading plan adopted on May 10, 2024.
• Following the transaction, Azoy directly owns 19,070 shares of Arcus Biosciences common stock.
• The filing also notes that 1,357 shares were purchased on May 31, 2024, through the company's Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a Rule 10b5-1 trading plan. It doesn't necessarily reflect a positive or negative outlook on the company's future.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates that a high ranking officer is selling shares.

Stakeholder Impact

• The sale of shares by a company officer could be perceived neutrally or slightly negatively by shareholders, depending on the context and the officer's overall holdings.

Key Dates